Latest Commercial Strategy News

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.

Environmental Clean Technologies (ASX: ECT) has completed a pilot Rapid Electrothermal Mineralisation system that delivers 18 times the power of its lab prototype, enabling additive-free, in-situ PFAS destruction and targeting a field demonstration in H2 2026.

Temas Resources is on track to fully commission its Ontario metallurgical lab by July 2026, initiating large-scale testing of La Blache project material to refine its proprietary RCL technology and support commercialization.

ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.

Optiscan Imaging has reached the halfway recruitment milestone in its first in-human breast cancer study, advancing its regulatory and commercial ambitions with promising clinical data and expanded trial sites.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.

Provaris Energy's proprietary liquified CO2 tank design has cleared a crucial Concept Selection milestone with Yinson, broadening its application beyond floating storage units to carriers and terminals, and advancing its path towards commercialisation.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.

Gold Hydrogen is accelerating Helium development at its Ramsay Project, leveraging exceptional purity results and independent modelling amid a tightening global Helium supply.

ION Video has appointed former Apple executive Kelli Richards as its inaugural Advisory Board member, aiming to leverage her Silicon Valley connections and media tech expertise to accelerate commercialisation.